Literature DB >> 34383225

What conservative interventions can improve the long-term quality of life, depression, and anxiety of individuals with stable COPD? A systematic review and meta-analysis.

Zejun Liang1,2, Qian Wang1,2, Chenying Fu3, Rui Liu1,2, Lu Wang1,2, Gaiqin Pei1,2, Lin Xu1,2, Chengqi He1,2, Quan Wei4,5.   

Abstract

PURPOSE: Many conservative interventions are used in the management of stable chronic obstructive pulmonary disease (COPD). It could be helpful for the prescribers to know what the evidence suggests about the effects of these interventions on the long-term quality of life (QoL), depression, and anxiety. This study aimed to summarize the rationale for the use of conservative interventions to improve the long-term QoL, depression, and anxiety in patients with stable COPD.
METHODS: The MEDLINE, Embase, Cochrane Library, and Web of Science databases were searched from database inception to December 2019. Randomized clinical trials (RCTs) investigating the long-term effects of conservative interventions on three parameters, including QoL, depression, and anxiety in patients with COPD were eligible for further analysis. To improve methodological rigor, only RCTs examining these parameters as primary outcomes were included. The standardized mean differences (SMD) with 95% confidence intervals (CIs) were calculated using random effects models. Quality of evidence was rated using the updated version of Van Tulder's criteria.
RESULTS: Thirty-eight RCTs were identified. Regarding long-term depression, there was moderate evidence supporting cognitive behavioral therapy compared with usual care in patients with COPD; regarding the long-term QoL of patients with COPD, there was limited evidence supporting walking programs, supplementary sugarcane bagasse dietary fiber, roflumilast, and tiotropium.
CONCLUSIONS: Cognitive behavioral therapy is effective in alleviating the long-term depression of patients with COPD. Evidence for other interventions was insufficient, making it difficult to draw conclusions in terms of their effectiveness on the long-term QoL, depression, and anxiety.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Anxiety; Chronic obstructive pulmonary disease; Cognitive behavioral therapy; Depression; Quality of life; Systematic review and meta-analysis

Mesh:

Year:  2021        PMID: 34383225     DOI: 10.1007/s11136-021-02965-4

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  41 in total

Review 1.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Authors:  Dave Singh; Alvar Agusti; Antonio Anzueto; Peter J Barnes; Jean Bourbeau; Bartolome R Celli; Gerard J Criner; Peter Frith; David M G Halpin; Meilan Han; M Victorina López Varela; Fernando Martinez; Maria Montes de Oca; Alberto Papi; Ian D Pavord; Nicolas Roche; Donald D Sin; Robert Stockley; Jørgen Vestbo; Jadwiga A Wedzicha; Claus Vogelmeier
Journal:  Eur Respir J       Date:  2019-05-18       Impact factor: 16.671

2.  The Impact of Depression and Anxiety on Chronic Obstructive Pulmonary Disease Acute Exacerbations: A prospective cohort study.

Authors:  Juan Huang; Yongjun Bian; Yuanchen Zhao; Zaiyan Jin; Li Liu; Guangxi Li
Journal:  J Affect Disord       Date:  2020-12-08       Impact factor: 4.839

Review 3.  Anxiety and depression-Important psychological comorbidities of COPD.

Authors:  Marsus I Pumar; Curt R Gray; James R Walsh; Ian A Yang; Tricia A Rolls; Donna L Ward
Journal:  J Thorac Dis       Date:  2014-11       Impact factor: 2.895

Review 4.  Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations.

Authors:  Ioanna Tsiligianni; Janwillem Kocks; Nikolaos Tzanakis; Nikolaos Siafakas; Thys van der Molen
Journal:  Prim Care Respir J       Date:  2011-09

Review 5.  Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis.

Authors:  Evan Atlantis; Paul Fahey; Belinda Cochrane; Sheree Smith
Journal:  Chest       Date:  2013-09       Impact factor: 9.410

6.  Anxiety and depression in COPD patients: The roles of gender and disease severity.

Authors:  Fabiano Di Marco; Massimo Verga; Manuela Reggente; Francesca Maria Casanova; Pierachille Santus; Francesco Blasi; Luigi Allegra; Stefano Centanni
Journal:  Respir Med       Date:  2006-03-13       Impact factor: 3.415

Review 7.  Depression and anxiety in patients with COPD.

Authors:  Abebaw M Yohannes; George S Alexopoulos
Journal:  Eur Respir Rev       Date:  2014-09

Review 8.  Anxiety and depression in COPD: current understanding, unanswered questions, and research needs.

Authors:  Janet Maurer; Venkata Rebbapragada; Soo Borson; Roger Goldstein; Mark E Kunik; Abebaw M Yohannes; Nicola A Hanania
Journal:  Chest       Date:  2008-10       Impact factor: 9.410

9.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Authors:  David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  Syst Rev       Date:  2015-01-01

10.  The physical, mental, and social impact of COPD in a population-based sample: results from the Longitudinal Aging Study Amsterdam.

Authors:  Frits M E Franssen; Dionne E Smid; Dorly J H Deeg; Martijn Huisman; Jan Poppelaars; Emiel F M Wouters; Martijn A Spruit
Journal:  NPJ Prim Care Respir Med       Date:  2018-08-10       Impact factor: 2.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.